Fall 2019 Course:


  • Jessica Sagers (TA)
  • Megan Krench (TA)
  • Monica Stanciu (TA)
  • Joseph Beyene
  • Audra Amasino
  • Kat Cleary
  • Kayarash Karimian
  • Rachel Cotton
  • Arthur de Garidel
  • Ira Male
  • Chensu Wang
  • Megan Woods
  • Nicole Black
  • Sam Rodriques
  • Bernie Siu
  • Amanda Chen
  • David Jackson
  • Yi-Li Min
  • Sivani Jonnalagadda
  • Leon Wert
  • Kat Tarasova
  • Jefte Drijvers
  • Juliana Soto-Giron
  • Wenjiang Ma
  • Fabio Pucci
  • Alastair Louey

Fall 2019 Curriculum

Spring 2019 Course:


  • Meg Krench (TA)
  • Jessica Sagers (TA)
  • Rebecca Fine (TA)
  • Will Orent (TA)
  • Ariel (Wei Hsi) Yeh
  • Abir Yamak
  • Yusuf Erkul
  • Anika Gupta
  • Anthony Zlaket
  • Brett Geiger
  • Christy Kuo
  • David Migl
  • David Thompson
  • Elaine Oberlick
  • Emeka Okoro
  • Hugo Caicedo
  • Ida Pavlichenko
  • Iris Braunstein
  • Jamie Zhan
  • Kevin Huang
  • Lena Afeyan
  • Michael Mazzola
  • Norah Owiti
  • Rachel Schecter
  • Soufiane Aboulhouda
  • Tanya Yatsunenko
  • Suan Tuang
  • Xiaobo Ke

Spring 2019 Curriculum

Spring 2019 Testimonials

Who is this for and why should you take this course?

So much of what’s important to success in the biotechnology sector is not as it seems – we have watched many people (including ourselves) learn difficult lessons through trial and error. This seems inefficient and possibly unnecessary. We believe that by exposing people with the potential to be this industry’s future leaders to advanced concept they might otherwise only learn later in their careers, they will better navigate the biotechnology industry and more quickly achieve their potential.

Our goal is to focus on concepts that are not yet taught in other courses in biotechnology. For example, drug pricing influences R&D yet is widely misunderstood, biotech business models that seem more stable can actually make a company more risky for both to employees and investors than business models that may appear less stable; and entrepreneurs often struggle to reconcile the straightforward economic promises of the business plans they are pitching with the obscure behavioral economics that govern how investors often make decisions.

We can probably all remember a single course, a single lecture, or even a single book that fundamentally changed our thinking and repeatedly guides our decisions. That’s the kind of course we have designed: a short, intense upgrade for people planning on a career in or related to biotechnology, whether in companies, as investors, as lawyers, academic founders, or government.

No prior knowledge of business is necessary, though an advanced background in the life sciences and/or healthcare is required, and therefore this course is limited to people who are currently in or recently graduated (within 2 years) from biomedical and related graduate programs or medical school or who majored in biology in college (graduated within last 4 years) and have work experience in biotech. Business and law school students may apply if they have a strong background in biomedical sciences. Not for current undergraduates.

Click below to learn about upcoming courses offered from RA Capital


If you have questions, contact Kathryn Roy at kroy@racap.com